Movatterモバイル変換


[0]ホーム

URL:


GB202404607D0 - RNA formulation - Google Patents

RNA formulation

Info

Publication number
GB202404607D0
GB202404607D0GBGB2404607.0AGB202404607AGB202404607D0GB 202404607 D0GB202404607 D0GB 202404607D0GB 202404607 AGB202404607 AGB 202404607AGB 202404607 D0GB202404607 D0GB 202404607D0
Authority
GB
United Kingdom
Prior art keywords
rna formulation
rna
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2404607.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Curevac SE
Original Assignee
GlaxoSmithKline Biologicals SA
Curevac SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, Curevac SEfiledCriticalGlaxoSmithKline Biologicals SA
Priority to GBGB2404607.0ApriorityCriticalpatent/GB202404607D0/en
Publication of GB202404607D0publicationCriticalpatent/GB202404607D0/en
Pendinglegal-statusCriticalCurrent

Links

Classifications

Landscapes

GBGB2404607.0A2024-03-292024-03-29RNA formulationPendingGB202404607D0 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
GBGB2404607.0AGB202404607D0 (en)2024-03-292024-03-29RNA formulation

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
GBGB2404607.0AGB202404607D0 (en)2024-03-292024-03-29RNA formulation

Publications (1)

Publication NumberPublication Date
GB202404607D0true GB202404607D0 (en)2024-05-15

Family

ID=91023429

Family Applications (1)

Application NumberTitlePriority DateFiling Date
GBGB2404607.0APendingGB202404607D0 (en)2024-03-292024-03-29RNA formulation

Country Status (1)

CountryLink
GB (1)GB202404607D0 (en)

Citations (102)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4373071A (en)1981-04-301983-02-08City Of Hope Research InstituteSolid-phase synthesis of polynucleotides
US4458066A (en)1980-02-291984-07-03University Patents, Inc.Process for preparing polynucleotides
US4500707A (en)1980-02-291985-02-19University Patents, Inc.Nucleosides useful in the preparation of polynucleotides
US4668777A (en)1981-03-271987-05-26University Patents, Inc.Phosphoramidite nucleoside compounds
US4973679A (en)1981-03-271990-11-27University Patents, Inc.Process for oligonucleo tide synthesis using phosphormidite intermediates
US5047524A (en)1988-12-211991-09-10Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
US5132418A (en)1980-02-291992-07-21University Patents, Inc.Process for preparing polynucleotides
US5153319A (en)1986-03-311992-10-06University Patents, Inc.Process for preparing polynucleotides
US5262530A (en)1988-12-211993-11-16Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
US5700642A (en)1995-05-221997-12-23Sri InternationalOligonucleotide sizing using immobilized cleavable primers
WO2002098443A2 (en)2001-06-052002-12-12Curevac GmbhStabilised mrna with an increased g/c content and optimised codon for use in gene therapy
WO2008016473A2 (en)2006-07-282008-02-07Applera CorporationDinucleotide mrna cap analogs
WO2008077592A1 (en)2006-12-222008-07-03Curevac GmbhMethod for purifying rna on a preparative scale by means of hplc
US7404969B2 (en)2005-02-142008-07-29Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2008103276A2 (en)2007-02-162008-08-28Merck & Co., Inc.Compositions and methods for potentiated activity of biologicaly active molecules
WO2008157688A2 (en)2007-06-192008-12-24Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeSynthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
WO2009086558A1 (en)2008-01-022009-07-09Tekmira Pharmaceuticals CorporationImproved compositions and methods for the delivery of nucleic acids
WO2009127060A1 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
WO2009149253A2 (en)2008-06-062009-12-10Uniwersytet WarszawskiMrna cap analogs
US20100036115A1 (en)1997-07-232010-02-11Sirna Therapeutics, Inc.Novel Compositions for the Delivery of Negatively Charged Molecules
WO2010021865A1 (en)2008-08-182010-02-25Merck Sharp & Dohme Corp.Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010048536A2 (en)2008-10-232010-04-29Alnylam Pharmaceuticals, Inc.Processes for preparing lipids
WO2010054406A1 (en)2008-11-102010-05-14Alnylam Pharmaceuticals, Inc.Novel lipids and compositions for the delivery of therapeutics
WO2010053572A2 (en)2008-11-072010-05-14Massachusetts Institute Of TechnologyAminoalcohol lipidoids and uses thereof
WO2010080724A1 (en)2009-01-122010-07-15Merck Sharp & Dohme Corp.Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010088537A2 (en)2009-01-292010-08-05Alnylam Pharmaceuticals, Inc.Improved lipid formulation
WO2010129709A1 (en)2009-05-052010-11-11Alnylam Pharmaceuticals, Inc.Lipid compositions
WO2011015347A1 (en)2009-08-052011-02-10Biontech AgVaccine composition comprising 5'-cap modified rna
US7893302B2 (en)2005-02-142011-02-22Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2011022460A1 (en)2009-08-202011-02-24Merck Sharp & Dohme Corp.Novel cationic lipids with various head groups for oligonucleotide delivery
WO2011043913A2 (en)2009-10-082011-04-14Merck Sharp & Dohme Corp.Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011076807A2 (en)2009-12-232011-06-30Novartis AgLipids, lipid compositions, and methods of using them
WO2011090965A1 (en)2010-01-222011-07-28Merck Sharp & Dohme Corp.Novel cationic lipids for oligonucleotide delivery
US20110256175A1 (en)2008-10-092011-10-20The University Of British ColumbiaAmino lipids and methods for the delivery of nucleic acids
WO2011149733A2 (en)2010-05-242011-12-01Merck Sharp & Dohme Corp.Novel amino alcohol cationic lipids for oligonucleotide delivery
WO2011153120A1 (en)2010-06-042011-12-08Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2011153493A2 (en)2010-06-032011-12-08Alnylam Pharmaceuticals, Inc.Biodegradable lipids for the delivery of active agents
WO2012006376A2 (en)2010-07-062012-01-12Novartis AgVirion-like delivery particles for self-replicating rna molecules
WO2012006378A1 (en)2010-07-062012-01-12Novartis AgLiposomes with lipids having an advantageous pka- value for rna delivery
WO2012019780A1 (en)2010-08-132012-02-16Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012031046A2 (en)2010-08-312012-03-08Novartis AgLipids suitable for liposomal delivery of protein-coding rna
WO2012031043A1 (en)2010-08-312012-03-08Novartis AgPegylated liposomes for delivery of immunogen-encoding rna
WO2012030901A1 (en)2010-08-312012-03-08Novartis AgSmall liposomes for delivery of immunogen-encoding rna
WO2012040184A2 (en)2010-09-202012-03-29Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2012044638A1 (en)2010-09-302012-04-05Merck Sharp & Dohme Corp.Low molecular weight cationic lipids for oligonucleotide delivery
US8158601B2 (en)2009-06-102012-04-17Alnylam Pharmaceuticals, Inc.Lipid formulation
WO2012054365A2 (en)2010-10-212012-04-26Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2012061259A2 (en)2010-11-052012-05-10Merck Sharp & Dohme Corp.Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
US20120202871A1 (en)2009-07-012012-08-09Protiva Biotherapeutics, Inc.Cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en)2009-07-012012-10-09Protiva Biotherapeutics, Inc.Lipid formulations for nucleic acid delivery
WO2012170930A1 (en)2011-06-082012-12-13Shire Human Genetic Therapies, IncLipid nanoparticle compositions and methods for mrna delivery
WO2013006825A1 (en)2011-07-062013-01-10Novartis AgLiposomes having useful n:p ratio for delivery of rna molecules
WO2013033563A1 (en)2011-08-312013-03-07Novartis AgPegylated liposomes for delivery of immunogen-encoding rna
US20130064894A1 (en)2011-08-312013-03-14Protiva Biotherapeutics, Inc.Novel cationic lipids and methods of use thereof
WO2013059475A1 (en)2011-10-182013-04-25Life Technologies CorporationAlkynyl-derivatized cap analogs, preparation and uses thereof
WO2013063468A1 (en)2011-10-272013-05-02Massachusetts Institute Of TechnologyAmino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres
US20130129785A1 (en)2010-05-102013-05-23Alnylam Pharmaceuticals, IncMethods and compositions for delivery of active agents
WO2013086373A1 (en)2011-12-072013-06-13Alnylam Pharmaceuticals, Inc.Lipids for the delivery of active agents
WO2013086354A1 (en)2011-12-072013-06-13Alnylam Pharmaceuticals, Inc.Biodegradable lipids for the delivery of active agents
US8466122B2 (en)2010-09-172013-06-18Protiva Biotherapeutics, Inc.Trialkyl cationic lipids and methods of use thereof
WO2013143700A2 (en)2012-03-272013-10-03Curevac GmbhArtificial nucleic acid molecules comprising a 5'top utr
US20140039032A1 (en)2011-12-122014-02-06Kyowa Hakko Kirin Co., Ltd.Lipid nano particles comprising cationic lipid for drug delivery system
WO2014136086A1 (en)2013-03-082014-09-12Novartis AgLipids and lipid compositions for the delivery of active agents
WO2014152659A1 (en)2013-03-142014-09-25Shire Human Genetic Therapies, Inc.Quantitative assessment for cap efficiency of messenger rna
WO2014152673A1 (en)2013-03-142014-09-25Shire Human Genetic Therapies, Inc.Quantitative assessment for cap efficiency of messenger rna
WO2015062738A1 (en)2013-11-012015-05-07Curevac GmbhModified rna with decreased immunostimulatory properties
US20150140070A1 (en)2013-10-222015-05-21Shire Human Genetic Therapies, Inc.Lipid formulations for delivery of messenger rna
WO2015074085A1 (en)2013-11-182015-05-21Arcturus Therapeutics, Inc.Ionizable cationic lipid for rna delivery
WO2015095340A1 (en)2013-12-192015-06-25Novartis AgLipids and lipid compositions for the delivery of active agents
WO2015095346A1 (en)2013-12-192015-06-25Novartis AgLipids and lipid compositions for the delivery of active agents
WO2015101416A1 (en)2013-12-302015-07-09Curevac GmbhMethods for rna analysis
WO2015188933A1 (en)2014-06-102015-12-17Curevac AgMethods and means for enhancing rna production
WO2015199952A1 (en)2014-06-252015-12-30Acuitas Therapeutics Inc.Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016022914A1 (en)2014-08-082016-02-11Moderna Therapeutics, Inc.Compositions and methods for the treatment of ophthalmic diseases and conditions
WO2016037053A1 (en)2014-09-052016-03-10Novartis AgLipids and lipid compositions for the delivery of active agents
WO2016107877A1 (en)2014-12-302016-07-07Curevac AgArtificial nucleic acid molecules
WO2016118725A1 (en)2015-01-232016-07-28Moderna Therapeutics, Inc.Lipid nanoparticle compositions
WO2016118724A1 (en)2015-01-212016-07-28Moderna Therapeutics, Inc.Lipid nanoparticle compositions
WO2016174271A1 (en)2015-04-302016-11-03Curevac AgImmobilized poly(n)polymerase
WO2016180430A1 (en)2015-05-082016-11-17Curevac AgMethod for producing rna
WO2016193206A1 (en)2015-05-292016-12-08Curevac AgA method for producing and purifying rna, comprising at least one step of tangential flow filtration
WO2016193226A1 (en)2015-05-292016-12-08Curevac AgMethod for adding cap structures to rna using immobilized enzymes
WO2017036580A1 (en)2015-08-282017-03-09Curevac AgArtificial nucleic acid molecules
WO2017053297A1 (en)2015-09-212017-03-30Trilink Biotechnologies, Inc.Compositions and methods for synthesizing 5'-capped rnas
WO2017066781A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en)2015-10-162017-04-20Modernatx, Inc.Trinucleotide mrna cap analogs
WO2017066791A1 (en)2015-10-162017-04-20Modernatx, Inc.Sugar substituted mrna cap analogs
WO2017066782A1 (en)2015-10-162017-04-20Modernatx, Inc.Hydrophobic mrna cap analogs
WO2017066793A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs and methods of mrna capping
WO2017066789A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs with modified sugar
WO2017070620A2 (en)2015-10-222017-04-27Modernatx, Inc.Broad spectrum influenza virus vaccine
WO2017070613A1 (en)2015-10-222017-04-27Modernatx, Inc.Human cytomegalovirus vaccine
WO2017075531A1 (en)2015-10-282017-05-04Acuitas Therapeutics, Inc.Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017099823A1 (en)2015-12-102017-06-15Modernatx, Inc.Compositions and methods for delivery of therapeutic agents
WO2017109161A1 (en)2015-12-232017-06-29Curevac AgMethod of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017112865A1 (en)2015-12-222017-06-29Modernatx, Inc.Compounds and compositions for intracellular delivery of agents
WO2017117530A1 (en)2015-12-302017-07-06Arcturus Therapeutics, Inc.Ionizable cationic lipid
WO2018075827A1 (en)2016-10-192018-04-26Arcturus Therapeutics, Inc.Trinucleotide mrna cap analogs
WO2018078053A1 (en)2016-10-262018-05-03Curevac AgLipid nanoparticle mrna vaccines
WO2019077001A1 (en)2017-10-192019-04-25Curevac AgNovel artificial nucleic acid molecules
WO2019092153A1 (en)2017-11-082019-05-16Curevac AgRna sequence adaptation
WO2020002525A1 (en)2018-06-272020-01-02Curevac AgNovel lassa virus rna molecules and compositions for vaccination

Patent Citations (112)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4458066A (en)1980-02-291984-07-03University Patents, Inc.Process for preparing polynucleotides
US4500707A (en)1980-02-291985-02-19University Patents, Inc.Nucleosides useful in the preparation of polynucleotides
US5132418A (en)1980-02-291992-07-21University Patents, Inc.Process for preparing polynucleotides
US4668777A (en)1981-03-271987-05-26University Patents, Inc.Phosphoramidite nucleoside compounds
US4973679A (en)1981-03-271990-11-27University Patents, Inc.Process for oligonucleo tide synthesis using phosphormidite intermediates
US4373071A (en)1981-04-301983-02-08City Of Hope Research InstituteSolid-phase synthesis of polynucleotides
US5153319A (en)1986-03-311992-10-06University Patents, Inc.Process for preparing polynucleotides
US5047524A (en)1988-12-211991-09-10Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
US5262530A (en)1988-12-211993-11-16Applied Biosystems, Inc.Automated system for polynucleotide synthesis and purification
US5700642A (en)1995-05-221997-12-23Sri InternationalOligonucleotide sizing using immobilized cleavable primers
US20100036115A1 (en)1997-07-232010-02-11Sirna Therapeutics, Inc.Novel Compositions for the Delivery of Negatively Charged Molecules
WO2002098443A2 (en)2001-06-052002-12-12Curevac GmbhStabilised mrna with an increased g/c content and optimised codon for use in gene therapy
US7404969B2 (en)2005-02-142008-07-29Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7893302B2 (en)2005-02-142011-02-22Sirna Therapeutics, Inc.Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2008016473A2 (en)2006-07-282008-02-07Applera CorporationDinucleotide mrna cap analogs
WO2008077592A1 (en)2006-12-222008-07-03Curevac GmbhMethod for purifying rna on a preparative scale by means of hplc
WO2008103276A2 (en)2007-02-162008-08-28Merck & Co., Inc.Compositions and methods for potentiated activity of biologicaly active molecules
WO2008157688A2 (en)2007-06-192008-12-24Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical CollegeSynthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap
WO2009086558A1 (en)2008-01-022009-07-09Tekmira Pharmaceuticals CorporationImproved compositions and methods for the delivery of nucleic acids
WO2009127060A1 (en)2008-04-152009-10-22Protiva Biotherapeutics, Inc.Novel lipid formulations for nucleic acid delivery
WO2009149253A2 (en)2008-06-062009-12-10Uniwersytet WarszawskiMrna cap analogs
WO2010021865A1 (en)2008-08-182010-02-25Merck Sharp & Dohme Corp.Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20110256175A1 (en)2008-10-092011-10-20The University Of British ColumbiaAmino lipids and methods for the delivery of nucleic acids
WO2010048536A2 (en)2008-10-232010-04-29Alnylam Pharmaceuticals, Inc.Processes for preparing lipids
WO2010053572A2 (en)2008-11-072010-05-14Massachusetts Institute Of TechnologyAminoalcohol lipidoids and uses thereof
US8450298B2 (en)2008-11-072013-05-28Massachusetts Institute Of TechnologyAminoalcohol lipidoids and uses thereof
WO2010054406A1 (en)2008-11-102010-05-14Alnylam Pharmaceuticals, Inc.Novel lipids and compositions for the delivery of therapeutics
WO2010080724A1 (en)2009-01-122010-07-15Merck Sharp & Dohme Corp.Novel lipid nanoparticles and novel components for delivery of nucleic acids
WO2010088537A2 (en)2009-01-292010-08-05Alnylam Pharmaceuticals, Inc.Improved lipid formulation
WO2010129709A1 (en)2009-05-052010-11-11Alnylam Pharmaceuticals, Inc.Lipid compositions
US20120128760A1 (en)2009-05-052012-05-24Alnylam Pharmaceuticals, Inc.Lipid compositions
US8158601B2 (en)2009-06-102012-04-17Alnylam Pharmaceuticals, Inc.Lipid formulation
US8569256B2 (en)2009-07-012013-10-29Protiva Biotherapeutics, Inc.Cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en)2009-07-012012-10-09Protiva Biotherapeutics, Inc.Lipid formulations for nucleic acid delivery
US20120202871A1 (en)2009-07-012012-08-09Protiva Biotherapeutics, Inc.Cationic lipids and methods for the delivery of therapeutic agents
WO2011015347A1 (en)2009-08-052011-02-10Biontech AgVaccine composition comprising 5'-cap modified rna
WO2011022460A1 (en)2009-08-202011-02-24Merck Sharp & Dohme Corp.Novel cationic lipids with various head groups for oligonucleotide delivery
WO2011043913A2 (en)2009-10-082011-04-14Merck Sharp & Dohme Corp.Novel cationic lipids with short lipid chains for oligonucleotide delivery
WO2011076807A2 (en)2009-12-232011-06-30Novartis AgLipids, lipid compositions, and methods of using them
WO2011090965A1 (en)2010-01-222011-07-28Merck Sharp & Dohme Corp.Novel cationic lipids for oligonucleotide delivery
US20130129785A1 (en)2010-05-102013-05-23Alnylam Pharmaceuticals, IncMethods and compositions for delivery of active agents
US20130150625A1 (en)2010-05-242013-06-13Brian W. BudzikNovel Amino Alcohol Cationic Lipids for Oligonucleotide Delivery
WO2011149733A2 (en)2010-05-242011-12-01Merck Sharp & Dohme Corp.Novel amino alcohol cationic lipids for oligonucleotide delivery
WO2011153493A2 (en)2010-06-032011-12-08Alnylam Pharmaceuticals, Inc.Biodegradable lipids for the delivery of active agents
US20120027803A1 (en)2010-06-032012-02-02Alnylam Pharmaceuticals, Inc.Biodegradable lipids for the delivery of active agents
WO2011153120A1 (en)2010-06-042011-12-08Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2012006378A1 (en)2010-07-062012-01-12Novartis AgLiposomes with lipids having an advantageous pka- value for rna delivery
WO2012006376A2 (en)2010-07-062012-01-12Novartis AgVirion-like delivery particles for self-replicating rna molecules
WO2012019780A1 (en)2010-08-132012-02-16Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012031046A2 (en)2010-08-312012-03-08Novartis AgLipids suitable for liposomal delivery of protein-coding rna
WO2012030901A1 (en)2010-08-312012-03-08Novartis AgSmall liposomes for delivery of immunogen-encoding rna
WO2012031043A1 (en)2010-08-312012-03-08Novartis AgPegylated liposomes for delivery of immunogen-encoding rna
US8466122B2 (en)2010-09-172013-06-18Protiva Biotherapeutics, Inc.Trialkyl cationic lipids and methods of use thereof
WO2012040184A2 (en)2010-09-202012-03-29Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
US20130178541A1 (en)2010-09-202013-07-11Matthew G. StantonNovel low molecular weight cationic lipids for oligonucleotide delivery
WO2012044638A1 (en)2010-09-302012-04-05Merck Sharp & Dohme Corp.Low molecular weight cationic lipids for oligonucleotide delivery
WO2012054365A2 (en)2010-10-212012-04-26Merck Sharp & Dohme Corp.Novel low molecular weight cationic lipids for oligonucleotide delivery
WO2012061259A2 (en)2010-11-052012-05-10Merck Sharp & Dohme Corp.Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
US20130225836A1 (en)2010-11-052013-08-29Merck Sharp & Dohme Corp.Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
WO2012170930A1 (en)2011-06-082012-12-13Shire Human Genetic Therapies, IncLipid nanoparticle compositions and methods for mrna delivery
WO2013006825A1 (en)2011-07-062013-01-10Novartis AgLiposomes having useful n:p ratio for delivery of rna molecules
WO2013033563A1 (en)2011-08-312013-03-07Novartis AgPegylated liposomes for delivery of immunogen-encoding rna
US20130064894A1 (en)2011-08-312013-03-14Protiva Biotherapeutics, Inc.Novel cationic lipids and methods of use thereof
WO2013059475A1 (en)2011-10-182013-04-25Life Technologies CorporationAlkynyl-derivatized cap analogs, preparation and uses thereof
WO2013063468A1 (en)2011-10-272013-05-02Massachusetts Institute Of TechnologyAmino acid derivates functionalized on the n- terminal capable of forming drug incapsulating microspheres
WO2013086354A1 (en)2011-12-072013-06-13Alnylam Pharmaceuticals, Inc.Biodegradable lipids for the delivery of active agents
WO2013086373A1 (en)2011-12-072013-06-13Alnylam Pharmaceuticals, Inc.Lipids for the delivery of active agents
US20140039032A1 (en)2011-12-122014-02-06Kyowa Hakko Kirin Co., Ltd.Lipid nano particles comprising cationic lipid for drug delivery system
WO2013143700A2 (en)2012-03-272013-10-03Curevac GmbhArtificial nucleic acid molecules comprising a 5'top utr
WO2014136086A1 (en)2013-03-082014-09-12Novartis AgLipids and lipid compositions for the delivery of active agents
WO2014152659A1 (en)2013-03-142014-09-25Shire Human Genetic Therapies, Inc.Quantitative assessment for cap efficiency of messenger rna
WO2014152673A1 (en)2013-03-142014-09-25Shire Human Genetic Therapies, Inc.Quantitative assessment for cap efficiency of messenger rna
US20150140070A1 (en)2013-10-222015-05-21Shire Human Genetic Therapies, Inc.Lipid formulations for delivery of messenger rna
WO2015062738A1 (en)2013-11-012015-05-07Curevac GmbhModified rna with decreased immunostimulatory properties
WO2015074085A1 (en)2013-11-182015-05-21Arcturus Therapeutics, Inc.Ionizable cationic lipid for rna delivery
US9593077B2 (en)2013-11-182017-03-14Arcturus Therapeutics, Inc.Ionizable cationic lipid for RNA delivery
US9567296B2 (en)2013-11-182017-02-14Arcturus Therapeutics, Inc.Ionizable cationic lipid for RNA delivery
WO2015095346A1 (en)2013-12-192015-06-25Novartis AgLipids and lipid compositions for the delivery of active agents
WO2015095340A1 (en)2013-12-192015-06-25Novartis AgLipids and lipid compositions for the delivery of active agents
WO2015101416A1 (en)2013-12-302015-07-09Curevac GmbhMethods for rna analysis
WO2015188933A1 (en)2014-06-102015-12-17Curevac AgMethods and means for enhancing rna production
WO2015199952A1 (en)2014-06-252015-12-30Acuitas Therapeutics Inc.Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
US20150376115A1 (en)2014-06-252015-12-31Acuitas Therapeutics Inc.Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016022914A1 (en)2014-08-082016-02-11Moderna Therapeutics, Inc.Compositions and methods for the treatment of ophthalmic diseases and conditions
WO2016037053A1 (en)2014-09-052016-03-10Novartis AgLipids and lipid compositions for the delivery of active agents
WO2016107877A1 (en)2014-12-302016-07-07Curevac AgArtificial nucleic acid molecules
WO2016118724A1 (en)2015-01-212016-07-28Moderna Therapeutics, Inc.Lipid nanoparticle compositions
WO2016118725A1 (en)2015-01-232016-07-28Moderna Therapeutics, Inc.Lipid nanoparticle compositions
WO2016174271A1 (en)2015-04-302016-11-03Curevac AgImmobilized poly(n)polymerase
WO2016180430A1 (en)2015-05-082016-11-17Curevac AgMethod for producing rna
WO2016193206A1 (en)2015-05-292016-12-08Curevac AgA method for producing and purifying rna, comprising at least one step of tangential flow filtration
WO2016193226A1 (en)2015-05-292016-12-08Curevac AgMethod for adding cap structures to rna using immobilized enzymes
WO2017036580A1 (en)2015-08-282017-03-09Curevac AgArtificial nucleic acid molecules
WO2017053297A1 (en)2015-09-212017-03-30Trilink Biotechnologies, Inc.Compositions and methods for synthesizing 5'-capped rnas
WO2017066781A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs with modified phosphate linkage
WO2017066797A1 (en)2015-10-162017-04-20Modernatx, Inc.Trinucleotide mrna cap analogs
WO2017066791A1 (en)2015-10-162017-04-20Modernatx, Inc.Sugar substituted mrna cap analogs
WO2017066782A1 (en)2015-10-162017-04-20Modernatx, Inc.Hydrophobic mrna cap analogs
WO2017066793A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs and methods of mrna capping
WO2017066789A1 (en)2015-10-162017-04-20Modernatx, Inc.Mrna cap analogs with modified sugar
WO2017070613A1 (en)2015-10-222017-04-27Modernatx, Inc.Human cytomegalovirus vaccine
WO2017070620A2 (en)2015-10-222017-04-27Modernatx, Inc.Broad spectrum influenza virus vaccine
WO2017075531A1 (en)2015-10-282017-05-04Acuitas Therapeutics, Inc.Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2017099823A1 (en)2015-12-102017-06-15Modernatx, Inc.Compositions and methods for delivery of therapeutic agents
WO2017112865A1 (en)2015-12-222017-06-29Modernatx, Inc.Compounds and compositions for intracellular delivery of agents
WO2017109161A1 (en)2015-12-232017-06-29Curevac AgMethod of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017117530A1 (en)2015-12-302017-07-06Arcturus Therapeutics, Inc.Ionizable cationic lipid
WO2018075827A1 (en)2016-10-192018-04-26Arcturus Therapeutics, Inc.Trinucleotide mrna cap analogs
WO2018078053A1 (en)2016-10-262018-05-03Curevac AgLipid nanoparticle mrna vaccines
WO2019077001A1 (en)2017-10-192019-04-25Curevac AgNovel artificial nucleic acid molecules
WO2019092153A1 (en)2017-11-082019-05-16Curevac AgRna sequence adaptation
WO2020002525A1 (en)2018-06-272020-01-02Curevac AgNovel lassa virus rna molecules and compositions for vaccination

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M PACKER, NATURE COMMUNICATIONS, 2021
no. 2036272-55-4

Similar Documents

PublicationPublication DateTitle
IL304263A (en)Self-circularized rna structure
GB202404607D0 (en)RNA formulation
IL319149A (en)Upadacitinib formulation
GB202416618D0 (en)Cannabidiol-based formulation
GB202411714D0 (en)Formulation
GB202417097D0 (en)New formulation
GB202416909D0 (en)New formulation
GB202407735D0 (en)Novel formulation
GB202417829D0 (en)Formulations
CA231602S (en)Cultivator
GB202302887D0 (en)Rna
GB202413603D0 (en)Formulation method
GB202500051D0 (en)RNA Molecule
GB202318884D0 (en)Formulation
GB202316857D0 (en)Cannabinoid-based formulation
GB202312814D0 (en)Formulation
GB202312220D0 (en)Formulation
GB202311622D0 (en)Formulation
GB202311439D0 (en)Formulation
IL317857A (en)Orellanine formulation
GB202308224D0 (en)Formulation
GB202307002D0 (en)Cannabinoid-based formulation
GB202306995D0 (en)Cannabinoid-based formulation
GB202306990D0 (en)Cannabinoid-based formulation
GB202307003D0 (en)Cannabinoid-based formulation

[8]ページ先頭

©2009-2025 Movatter.jp